Biogen Due after five years decreased by 12.1% to $10.90M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Due after five years shows a downward trend with a -36.8% CAGR.
other_available_for_sale_securities_debt_maturities_afte_476e01| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.20M | $42.80M | $24.00M | $18.70M | $13.50M | $12.00M | $12.10M | $16.60M | $15.70M | $12.40M | $10.90M |
| QoQ Change | — | -3.2% | -43.9% | -22.1% | -27.8% | -11.1% | +0.8% | +37.2% | -5.4% | -21.0% | -12.1% |
| YoY Change | — | — | — | — | -69.5% | -72.0% | -49.6% | -11.2% | +16.3% | — | — |